Search clinical trials for: BIIB132

Total 66 results

NightstaRx Ltd, a Biogen Company

Enrolling by invitation

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa (SOLSTICE)

Choroideremia | X-Linked Retinitis Pigmentosa

United States, United Kingdom, Netherlands, Germany, France, Brazil, Canada, Denmark, Finland
Biogen

Terminated

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

Spinocerebellar Ataxia Type 3

United States, Netherlands, Israel, Portugal, United Kingdom, Germany
Biogen
Denali Therapeutics Inc.

Completed

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

Healthy Volunteers

United States
Biogen
Denali Therapeutics Inc.

Recruiting

A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)

Parkinson Disease

United States, Netherlands, Italy, Spain, Israel, Canada, China, Germany, France, Austria, United Kingdom, Poland, Japan
Biogen
Denali Therapeutics Inc.

Terminated

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (LIGHTHOUSE)

Parkinson Disease

United States, Italy, Spain, Germany, France, United Kingdom
Biogen

Completed

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

Healthy Volunteer

United States
Biogen

Withdrawn

A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well (DAISY)

Ischemic Stroke
Biogen

Completed

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS)

X-Linked Retinitis Pigmentosa

United States, United Kingdom
NightstaRx Ltd, a Biogen Company

Completed

Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS)

X-Linked Retinitis Pigmentosa

United States, France, United Kingdom, Finland, Netherlands, Germany, Canada
Biogen
Denali Therapeutics Inc.

Completed

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

Healthy Volunteers

United States
Biogen

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115

Healthy Volunteer | Muscular Atrophy, Spinal

Korea, Republic of, Germany, Belgium, Netherlands, France, Italy, Poland, Canada, United Kingdom, Israel
Biogen

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

Healthy Volunteers

United States
Biogen

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants

Healthy Volunteer

United Kingdom, Sweden
Biogen

Completed

A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants

Healthy Volunteers

United States
Biogen

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

Healthy Volunteers

United States
Biogen

Active, not recruiting

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation (ALSpire)

Amyotrophic Lateral Sclerosis

United States, Netherlands, Italy, Canada
Biogen

Completed

A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants

Healthy Volunteers

United Kingdom
Biogen

Completed

Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants

Alzheimer's Disease

United States
Biogen

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States
Biogen
Eisai Co., Ltd.

Completed

A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers

Healthy Volunteers

United States
Biogen

Completed

Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers

Healthy Volunteers

Australia, China
Biogen

Terminated

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)

Alzheimer's Disease

United States, Spain, Italy, Taiwan, Australia, Denmark, Portugal, Korea, Republic of, Canada, Japan, France, United Kingdom, Austria, Germany
Biogen

Terminated

Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

Supranuclear Palsy, Progressive

United States
Biogen

Active, not recruiting

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Alzheimer's Disease

Korea, Republic of, United States, Spain, Belgium, Italy, Australia, Canada, Switzerland, Portugal, Taiwan, France, Poland, Germany, Netherlands, Sweden, Austria, Denmark, Japan, United Kingdom, Finland
Biogen

Completed

A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteer

United States
Biogen

Completed

Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

Multiple Sclerosis | Acute Optic Neuritis

United States
Biogen

Completed

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants

Multiple Sclerosis | Central Nervous System (CNS) Demyelinating Disease

United Kingdom
Biogen

Completed

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy (CN002-003)

Progressive Supranuclear Palsy

United States
Biogen

Completed

Efficacy and Safety of BIIB111 for the Treatment of Choroideremia (STAR)

Choroideremia

United States, Finland, France, Denmark, Netherlands, Germany, United Kingdom, Canada
Biogen

Completed

A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

Healthy Volunteer

United States
Biogen

Terminated

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities (EVOLVE)

Cognitive Dysfunction | Alzheimer's Disease

United States
Biogen

Terminated

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)

Alzheimer's Disease

United States, Spain, Belgium, Switzerland, Poland, Canada, Italy, Germany, Netherlands, Sweden, France, Japan, Finland
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteers

United States
Biogen

Terminated

Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)

Supranuclear Palsy, Progressive

United States, France, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, Austria, Canada, Germany, Japan, Australia, Greece
Biogen

Completed

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY)

Cognitive Impairment Associated With Schizophrenia

Spain, United States, Germany, Japan, United Kingdom
Biogen

Completed

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 (GEMINI)

Choroideremia

United States, Germany, France
University of California, San Francisco

Terminated

BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES (TauBasket)

Nonfluent Aphasia, Progressive | Primary Tauopathies | Corticobasal Degeneration Syndrome | Frontotemporal Lobar Degeneration With Tau Inclusions | MAPT Mutation Carriers, Symptomatic | Traumatic Encephalopathy Syndrome

United States
Biogen

Completed

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Active, not recruiting

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease (ENVISION)

Alzheimer's Disease

Canada, United States, Spain, Italy, Australia, Belgium, Portugal, Korea, Republic of, United Kingdom, France, Germany, Sweden, Japan, Brazil, Finland, Poland, Mexico
Biogen

Completed

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Solid Tumors

United States
Biogen

Completed

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects

Tauopathies

United States
Biogen

Completed

Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)

Healthy

United States
Biogen

Completed

Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

Alzheimer's Disease

United States
Sage Therapeutics
Biogen

Recruiting

Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Biogen

Completed

BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects

Healthy

Netherlands, United States
Biogen

Completed

Long-Term Assessment of Remyelinating Therapy (RENEWED)

Acute Optic Neuritis

Sweden, Spain, United Kingdom, Germany, Canada, Denmark, Hungary, Belgium, Czechia, Australia, Italy
Biogen

Completed

BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Russian Federation
Biogen

Terminated

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) (AFFINITY)

Multiple Sclerosis

United States, Italy, Spain, Belgium, Germany, Switzerland, Australia, Hungary, France, Poland, United Kingdom, Czechia, Israel, Canada, Netherlands
Biogen

Active, not recruiting

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

Healthy Volunteer

United States
Biogen

Completed

A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers

Healthy

United States

3

Subscribe